dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: M1: Aminopeptidase N (type: enzyme)
Target: Leukotriene A<sub>4</sub> hydrolase

Ligand: 4-OMe-ARM1 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Effect of Modifier Structure on the Activation of Leukotriene A<sub>4</sub> Hydrolase Aminopeptidase Activity.
Published in: J Med Chem

Ligand: acebilustat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Patent): Methods of inhibiting leukotriene a4 hydrolase

Ligand: bestatin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.400000095367432 pKi
Reference (Journal): Leukotriene A4 hydrolase. Inhibition by bestatin and intrinsic aminopeptidase activity establish its functional resemblance to metallohydrolase enzymes.
Published in: J Biol Chem

Ligand: compound 1a [PMID: 25692029] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.270000457763672 pKi
Reference (Journal): Structure-based dissection of the active site chemistry of leukotriene A4 hydrolase: implications for M1 aminopeptidases and inhibitor design.
Published in: Chem Biol

Ligand: compound 1a [PMID: 25692029] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.270000457763672 pKi
Reference (Journal): Long-lasting oral analgesic effects of N-protected aminophosphinic dual ENKephalinase inhibitors (DENKIs) in peripherally controlled pain.
Published in: Pharmacol Res Perspect

Ligand: DG-051 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.3 pIC50
Reference (Journal): Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis.
Published in: J Med Chem

Ligand: kelatorphan (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pKi
Reference (Journal): Kelatorphan and related analogs: potent and selective inhibitors of leukotriene A4 hydrolase
Published in: Bioorganic and Medicinal Chemistry Letters

Ligand: LYS006 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Patent): Heteroaryl butanoic acid derivatives as lta4h inhibitors

Ligand: SC-22716 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.699999809265137 pIC50
Reference (Journal): Structure-activity relationship studies on 1-[2-(4-Phenylphenoxy)ethyl]pyrrolidine (SC-22716), a potent inhibitor of leukotriene A(4) (LTA(4)) hydrolase.
Published in: J Med Chem
Target family: M1: Aminopeptidase N (type: enzyme)
Target: Puromycin-sensitive aminopeptidase

Ligand: ANTAQ (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 5.539999961853027 pIC50
Reference (Journal): Fluorescent bioprobes for visualization of puromycin-sensitive aminopeptidase in living cells.
Published in: Bioorg Med Chem Lett

Ligand: puromycin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.610000133514404 pIC50
Reference (Journal): Highly functionalized tetrahydropyridines are cytotoxic and selective inhibitors of human puromycin sensitive aminopeptidase.
Published in: Eur J Med Chem
Target family: M24: Methionyl aminopeptidase (type: enzyme)
Target: peptidase D

Ligand: phosphoenolpyruvic acid (Metabolite)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Inhibition of prolidase by phosphoenolpyruvate is biphasic. avoidance of endogenous-metabolite inactivation by cooperativity within an enzyme dimer.
Published in: Bioorg Med Chem Lett
Target family: M24: Methionyl aminopeptidase (type: enzyme)
Target: X-prolyl aminopeptidase 1

Ligand: apstatin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.679999828338623 pIC50
Reference (Journal): Apstatin analogue inhibitors of aminopeptidase P, a bradykinin-degrading enzyme.
Published in: J Med Chem
Target family: M24: Methionyl aminopeptidase (type: enzyme)
Target: X-prolyl aminopeptidase 2

Ligand: apstatin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 5.539999961853027 pIC50
Reference (Journal): Apstatin analogue inhibitors of aminopeptidase P, a bradykinin-degrading enzyme.
Published in: J Med Chem

Ligand: apstatin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.190000057220459 pKi
Reference (Journal): Apstatin analogue inhibitors of aminopeptidase P, a bradykinin-degrading enzyme.
Published in: J Med Chem
Target family: M24: Methionyl aminopeptidase (type: enzyme)
Target: Methionyl aminopeptidase 2

Ligand: beloranib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732.
Published in: J Mol Endocrinol
Target family: M24: Methionyl aminopeptidase (type: enzyme)
Target: Methionyl aminopeptidase 1

Ligand: compound 14 [PMID: 23634668] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.03000020980835 pEC50
Reference (Journal): Pyridinylquinazolines selectively inhibit human methionine aminopeptidase-1 in cells.
Published in: J Med Chem
Target family: M24: Methionyl aminopeptidase (type: enzyme)
Target: X-prolyl aminopeptidase 2

Ligand: compound 6 [PMID: 10395480] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.639999866485596 pIC50
Reference (Journal): Apstatin analogue inhibitors of aminopeptidase P, a bradykinin-degrading enzyme.
Published in: J Med Chem
Target family: M24: Methionyl aminopeptidase (type: enzyme)
Target: Methionyl aminopeptidase 2

Ligand: XMT-1191 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8 pIC50
Reference (Journal): Anti-angiogenic and Anti-tumor Activity of XMT-1107, a Fumagillol-derived Polymer Conjugate,  and its in vivo Release Product XMT-1191.
Published in: Proc Am Assoc Cancer Res

Ligand: M8891 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.269999980926514 pIC50
Reference (Journal): Identification of Methionine Aminopeptidase-2 (MetAP-2) Inhibitor <b>M8891</b>: A Clinical Compound for the Treatment of Cancer.
Published in: J Med Chem
Target family: M28: Aminopeptidase Y (type: enzyme)
Target: Folate hydrolase (prostate-specific membrane antigen) 1

Ligand: compound 8d [PMID: 15027864] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.520000457763672 pKi
Reference (Journal): Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents.
Published in: J Med Chem

Ligand: capromab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (1996)
Median affinity:  -

Ligand: vipivotide tetraxetan (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.430000305175781 pKi
Reference (Journal): Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Published in: J Nucl Med
Target family: M28: Aminopeptidase Y (type: enzyme)
Target: glutaminyl-peptide cyclotransferase like

Ligand: BI-43 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.400000095367432 pIC50
Reference (Journal): X-ray Structure-Guided Discovery of a Potent Benzimidazole Glutaminyl Cyclase Inhibitor That Shows Activity in a Parkinson's Disease Mouse Model.
Published in: J Med Chem

Ligand: QP5020 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.1899995803833 pIC50
Reference (Journal): Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy.
Published in: Signal Transduct Target Ther

Ligand: QP5038 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.479999542236328 pIC50
Reference (Journal): Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy.
Published in: Signal Transduct Target Ther

Ligand: SEN177 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.489999771118164 pIC50
Reference (Journal): Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy.
Published in: Signal Transduct Target Ther

Ligand: varoglutamstat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.010000228881836 pIC50
Reference (Journal): Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy.
Published in: Signal Transduct Target Ther
Target family: M2: Angiotensin-converting enzymes (ACE and ACE2) (type: enzyme)
Target: Angiotensin-converting enzyme 2

Ligand: BCY15291 (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.050000190734863 pKi
Reference (Journal): Structure-Guided Chemical Optimization of Bicyclic Peptide (<i>Bicycle</i>) Inhibitors of Angiotensin-Converting Enzyme 2.
Published in: J Med Chem

Ligand: compound 28 [PMID: 18324760] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.899999618530273 pKi
Reference (Journal): Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2.
Published in: J Med Chem

Ligand: CPS4 (Peptide)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 6.199999809265137 pIC50
Reference (Journal): Discovery of Small Anti-ACE2 Peptides to Inhibit SARS-CoV-2 Infectivity.
Published in: Adv Ther (Weinh)

Ligand: DX600 (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.550000190734863 pKi
Reference (Journal): Novel peptide inhibitors of angiotensin-converting enzyme 2.
Published in: J Biol Chem
Target family: M2: Angiotensin-converting enzymes (ACE and ACE2) (type: enzyme)
Target: Angiotensin-converting enzyme

Ligand: cilazapril (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Primary target: yes
Median affinity:  -
Target family: M2: Angiotensin-converting enzymes (ACE and ACE2) (type: enzyme)
Target: Angiotensin-converting enzyme 2

Ligand: DX600 (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.920000076293945 pKi
Reference (Journal): Angiotensin converting enzyme versus angiotensin converting enzyme-2 selectivity of MLN-4760 and DX600 in human and murine bone marrow-derived cells.
Published in: Eur J Pharmacol

Ligand: MLN-4760 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.359999656677246 pIC50
Reference (Journal): Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2.
Published in: J Med Chem

Ligand: XNT [PMID: 18391097] (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 4.699999809265137 pEC50
Reference (Journal): Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents.
Published in: Hypertension
Target family: M2: Angiotensin-converting enzymes (ACE and ACE2) (type: enzyme)
Target: Angiotensin-converting enzyme

Ligand: fosinoprilat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1991)
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: in vitro and preclinical in vivo pharmacology.
Published in: J Cardiovasc Pharmacol

Ligand: imidaprilat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA
Primary target: yes
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Imidapril: a review of its use in essential hypertension, Type 1 diabetic nephropathy and chronic heart failure.
Published in: Drugs

Ligand: temocaprilat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.4399995803833 pIC50
Reference (Journal): Angiotensin-converting enzyme inhibitors: perhydro-1,4-thiazepin-5-one derivatives.
Published in: J Med Chem

Ligand: trandolapril (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1996)
Primary target: yes
Median affinity: 7.800000190734863 pIC50
Reference (Journal): Compared properties of trandolapril, enalapril, and their diacid metabolites.
Published in: J Cardiovasc Pharmacol

Ligand: trandolaprilat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1996)
Primary target: yes
Median affinity: 8.5 pIC50
Reference (Journal): Compared properties of trandolapril, enalapril, and their diacid metabolites.
Published in: J Cardiovasc Pharmacol

Ligand: zofenopril (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Primary target: yes
Median affinity:  -

Ligand: zofenoprilat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.
Published in: J Med Chem

Ligand: zofenoprilat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA
Primary target: no
Median affinity: 9.399999618530273 pKi
Reference (Journal): Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.
Published in: J Med Chem
Target family: M2: Angiotensin-converting enzymes (ACE and ACE2) (type: enzyme)
Target: Angiotensin-converting enzyme 2

Ligand: Abz-Ser-Pro-Tyr(NO2)-OH (Peptide)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Development of intramolecularly quenched fluorescent peptides as substrates of angiotensin-converting enzyme 2.
Published in: Anal Biochem
Target family: M2: Angiotensin-converting enzymes (ACE and ACE2) (type: enzyme)
Target: Angiotensin-converting enzyme

Ligand: captopril (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1981)
Primary target: yes
Median affinity: 8.399999618530273 pKi
Reference (Journal): Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I.
Published in: Mol Pharmacol

Ligand: benazeprilat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1991)
Primary target: yes
Median affinity: 6.599999904632568 pIC50
Reference (Journal): Angiotensin-converting enzyme inhibitors in veterinary medicine.
Published in: Curr Pharm Des

Ligand: benazepril (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1991)
Primary target: yes
Median affinity: 8.800000190734863 pIC50
Reference (Journal): Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives.
Published in: J Med Chem
Target family: M2: Angiotensin-converting enzymes (ACE and ACE2) (type: enzyme)
Target: Angiotensin-converting enzyme 2

Ligand: BCY15291 (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.359999656677246 pKd
Reference (Journal): Structure-Guided Chemical Optimization of Bicyclic Peptide (<i>Bicycle</i>) Inhibitors of Angiotensin-Converting Enzyme 2.
Published in: J Med Chem
Target family: M2: Angiotensin-converting enzymes (ACE and ACE2) (type: enzyme)
Target: Angiotensin-converting enzyme

Ligand: cilazaprilat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Primary target: yes
Median affinity: 8.699999809265137 pIC50
Reference (Journal): A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor.
Published in: Br J Clin Pharmacol

Ligand: enalapril (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1985)
Primary target: yes
Median affinity: 4.300000190734863 pIC50
Reference (Journal): Compared properties of trandolapril, enalapril, and their diacid metabolites.
Published in: J Cardiovasc Pharmacol

Ligand: enalaprilat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1985)
Primary target: yes
Median affinity: 7.5 pIC50
Reference (Journal): Compared properties of trandolapril, enalapril, and their diacid metabolites.
Published in: J Cardiovasc Pharmacol

Ligand: fasidotril (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -

Ligand: fasidotrilat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8 pKi
Reference (Journal): Protease inhibitors in the clinic.
Published in: Med Chem

Ligand: fosinopril (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1991)
Primary target: yes
Median affinity:  -
Target family: M79: Prenyl protease 2 (type: enzyme)
Target: Ras converting CAAX endopeptidase 1

Ligand: CID16197121 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.730000019073486 pIC50
Reference (Webpage): Human Ras-Converting Enzyme Inhibition Assay  AID 588849.

Ligand: compound 3 [PMID: 17942791] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 5.050000190734863 pIC50
Reference (Journal): Small-molecule inhibitors of the Rce1p CaaX protease.
Published in: J Biomol Screen
Target family: MAPKAPK subfamily (type: enzyme)
Target: MAPK activated protein kinase 3

Ligand: compound 16 [PMID: 17480064] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.679999828338623 pIC50
Reference (Journal): Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).
Published in: J Med Chem
Target family: MAPKAPK subfamily (type: enzyme)
Target: MAPK activated protein kinase 2

Ligand: compound 16 [PMID: 17480064] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.069999694824219 pIC50
Reference (Journal): Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).
Published in: J Med Chem

Ligand: compound 16 [PMID: 18945615] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.289999961853027 pIC50
Reference (Journal): Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity.
Published in: Bioorg Med Chem Lett

Ligand: compound 33 [PMID: 19364658] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.409999847412109 pIC50
Reference (Journal): Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).
Published in: Bioorg Med Chem

Ligand: compound 8 [PMID: 17480064] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.769999980926514 pIC50
Reference (Journal): Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).
Published in: J Med Chem

Ligand: gamcemetinib (Synthetic organic)
Interaction type: Inhibitor
Action: Irreversible inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.809999942779541 pIC50
Reference (Journal): Discovery of CC-99677, a selective targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune disorders.
Published in: Transl Res

Ligand: MK2a inhibitor (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.480000019073486 pKi
Reference (Journal): Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38alpha(MAPK) inhibitors in Werner syndrome cells.
Published in: Bioorg Med Chem Lett

Ligand: PF-3644022 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.279999732971191 pIC50
Reference (Journal): A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation.
Published in: J Pharmacol Exp Ther

Ligand: PF-3644022 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.520000457763672 pKi
Reference (Journal): A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation.
Published in: J Pharmacol Exp Ther